| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000038829 |
| Receipt No. | R000044062 |
| Scientific Title | Anti-wrinkle function test in use of product "4625-HK202MM-G" |
| Date of disclosure of the study information | 2019/12/10 |
| Last modified on | 2020/06/09 (Ver. 2) |
| Basic information | ||
| Public title | Anti-wrinkle function test in use of product "4625-HK202MM-G" | |
| Acronym | Efficacy test in use of product "4625-HK202MM-G" | |
| Scientific Title | Anti-wrinkle function test in use of product "4625-HK202MM-G" | |
| Scientific Title:Acronym | Efficacy test in use of product "4625-HK202MM-G" | |
| Region |
|
|
| Condition | ||
| Condition | Healthy volunteer | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | To confirm the effect of improvement on skin wrinkles using cream "4625-HK202MM-G" |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | Wrinkle assessment of eye corner, Wrinkle evaluation using the replica of eye corner |
| Key secondary outcomes | Questionnaire, Skin condition, Wrinkle assessment, Wrinkle evaluation using the replica of eye corner |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Randomized |
| Randomization unit | Individual |
| Blinding | Double blind -all involved are blinded |
| Control | Placebo |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 2 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | The test product "4625-HK202MM-G" is applied twice a day for 9 weeks to the eye corners of the half-faces randomly assigned by the person in charge of assignment. | |
| Interventions/Control_2 | The pracebo product "4625-HK202MM-P" is applied twice a day for 9 weeks to the eye corners of the half-faces randomly assigned by the person in charge of assignment. | |
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Female | |||
| Key inclusion criteria | Those who have main wrinkles (wrinkle grade: from 3 to 5) in the both eye corners | |||
| Key exclusion criteria | 1.Wrinkle grade scores on the left and right eye corners in the pre-examination are significantly different (as a guide, there is a difference of +- 1.0 or more between left and right)
2.Persons who may act that tends to cause a difference in left and right wrinkles in the their daily lives (such as those who are mainly engaged in driving cars) 3.Those who have factors in the evaluation site of the skin that may affect the result of the test (diseases such as atopic dermatitis and urticaria, inflammation, eczema, trauma, acne, pimples, warts, etc., or traces entities) 4.Those who have undergone cosmetic treatment (botox injection, hyaluronic acid or collagen injection, photofacial treatment, etc.) that affects the evaluation site, or who are scheduled to receive during the test period 5.Those who have received or plan to receive special skin care (beauty salon, aesthetics, etc.) within 4 weeks or during the test period. 6.Those who use skin care products constantly, such as cosmetics, quasi-drugs, healthy foods, etc. that have the same or related effectiveness as the efficacy in this study (against whrinkles). 7.Those who have changed or have started to use cosmetics such as basic care or sunscreen agents, and healthy food within 4 weeks before the test. 8.Persons who have been exposed to ultraviolet rays beyond their daily lives, such as prolonged work outdoors, exercise, sea bathing, leisure, etc. within 4 weeks before the test period, or who are scheduled to do so during the test period 9.Persons working night shifts and day/night shifts 10.At the time of obtaining consent, a person who has received treatment (hormone replacement therapy, drug therapy, exercise therapy, diet, etc.) at a medical institution for the treatment or prevention of illness, or a condition that requires treatment Who is judged |
|||
| Target sample size | 50 | |||
| Research contact person | |||||||
| Name of lead principal investigator |
|
||||||
| Organization | Medical Corpoation Kenshokai
Fukushima Healthcare Center |
||||||
| Division name | Department of Internal Medicine, Neurosurgery | ||||||
| Zip code | 553-0004 | ||||||
| Address | 2-12-16, Tamagawa Fukushima-ku, Osaka, Japan | ||||||
| TEL | 81-(0)6-6882-1130 | ||||||
| s.kondo@drc-web.co.jp | |||||||
| Public contact | |||||||
| Name of contact person |
|
||||||
| Organization | Ezaki Glico Co., Ltd. | ||||||
| Division name | Institute of Health Sciences | ||||||
| Zip code | 555-8502 | ||||||
| Address | 4-6-5, Utajima, Nishiyodogawa-ku, Osaka, Japan | ||||||
| TEL | +81-6-6477-8425 | ||||||
| Homepage URL | |||||||
| hiroko.yatsuhashi@glico.com | |||||||
| Sponsor | |
| Institute | Glico Nutrition Co., Ltd. |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Glico Nutrition Co., Ltd. |
| Organization | |
| Division | |
| Category of Funding Organization | Profit organization |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | Brain Care Clinic Ethics Review Committee |
| Address | Samon-Cho 13, Isobe Build. 2F, Shinjyuku-ku, Tokyo |
| Tel | 81-(0)6-6882-1130 |
| ethics_board@drc-web.co.jp | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| Result | |
| URL related to results and publications | |
| Number of participants that the trial has enrolled | |
| Results | |
| Results date posted | |
| Results Delayed | |
| Results Delay Reason | |
| Date of the first journal publication of results | |
| Baseline Characteristics | |
| Participant flow | |
| Adverse events | |
| Outcome measures | |
| Plan to share IPD | |
| IPD sharing Plan description | |
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Other | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000044062 |